UNSPSC 51373440: Codeine/guaifenesin/pheniramine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.

UNSPSC 51373440 Codeine/guaifenesin/pheniramine is a Commodity code under which state and local governments procure pharmaceutical products, including naloxone, drug deactivation systems, and generic multi-source pharmaceuticals and over-the-counter medications for community health, public safety, and institutional use. Recent solicitations show demand for both emergency medical supplies (naloxone kits) and broad-based generic pharmaceutical inventories distributed across multiple public health facilities. Issuing bodies include county health departments and state cooperative purchasing alliances; Seminole County, Florida and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, are recent active buyers. The code does not show explicit set-aside designations in current opportunities, though vendors must meet standard compliance requirements including drug-free workplace certification, E-Verify compliance, cGMP certification, and Drug Supply Chain Security Act (DSCSA) compliance.

Recent activity concentrates in Florida and Minnesota. Seminole County issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, with a response deadline of July 26, 2023. MMCAP posted RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products distributed across Minnesota and Oregon state and local facilities, with proposals due March 26, 2026; awarded vendors will supply products through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson) effective July 1, 2026. Both solicitations require detailed product information including NDC codes and compliance with FDA requirements and expiration-date standards. Pricing evaluation in the MMCAP procurement weights price competitiveness at 75 percent, with administrative fees of 3 percent assessed on contract purchases and performance penalties ranging from $200 to $1,500 per violation.